search
Back to results

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

Primary Purpose

Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
40 mg MSB11022
40 mg MSB11022
Sponsored by
Fresenius Kabi SwissBioSim GmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Rheumatoid Arthritis focused on measuring Biosimilar, Adalimumab, MSB11022

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Willing and able to sign the informed consent form (ICF).
  2. Healthy male subjects and female subjects of non-childbearing and childbearing potential.
  3. Aged 18 to 55 years, inclusive, at screening.
  4. Have all screening results (vital signs, physical examination, clinical laboratory tests, 12-lead ECG) within the normal range or outside the normal range but assessed as not clinically significant by the Investigator.
  5. Body weight between 50.0 and 100.0 kg, inclusive, and a body mass index between 18.5 and 30.0 kg/m2, inclusive.
  6. Male subjects must be either surgically sterile or willing to use contraceptive methods until 5 months after the dose of investigational medicinal product (IMP).
  7. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and before randomization. WOCBP must agree to use highly effective methods of contraception to prevent pregnancy for at least 4 weeks before randomization until 5 months after the dose of IMP. For all postmenopausal female subjects, serum follicle-stimulating hormone (FSH) is tested at screening to identify their postmenopausal status.
  8. Willing and able to comply with scheduled visits, treatment plan, laboratory tests and all other study procedures.

Exclusion Criteria:

  1. Female subjects must not be pregnant or lactating at screening through at least 5 months after the last treatment with IMP.
  2. A history and/or current presence of clinically significant atopic allergy (eg, asthma including childhood asthma), hypersensitivity or allergic reactions (either spontaneous or following drug administration), including known or suspected clinically relevant drug hypersensitivity to any components of the study drug formulations, comparable drugs, or to latex. Mild hay fever is allowed if outside of acute exacerbation requiring treatment. Assessment of clinical significance of reported atopic or allergic condition in medical history of participant is at Investigator decision.
  3. Have either active or latent tuberculosis (TB) as indicated by a positive QuantiFERON®-TB Gold test or have a history of TB. Subjects who have an indeterminate QuantiFERON-TB Gold test result may be re-tested once during screening. If the re-test result is negative, the subject is eligible to participate in the study. If the re-test result is indeterminate again or positive, the subject is NOT eligible to participate in the study.
  4. Lifetime history of invasive systemic fungal infections (eg, histoplasmosis) or other opportunistic infections, including recurrent or chronic local fungal infections.
  5. Have had a serious infection (associated with hospitalization and/or which required intravenous anti-infectives or intravenous antibiotics) within 6 months prior to study drug administration and/or a significant infection (excluding resolved infections like a mild common cold) within 2 weeks prior to the screening or during the screening period unless the infection has resolved completely within 2 weeks before admission.
  6. Have had herpes zoster

    1. within the last year, or
    2. more than 2 herpes zoster infections in their lifetime prior to randomization.
  7. History or presence (at time of screening or randomization) of frequent (ie, requiring treatment more than 3 times a year), chronic or recurrent infections.
  8. Have previously been exposed to adalimumab or approved or proposed adalimumab biosimilar drugs if known. Have been exposed to any anti-tumor necrosis factor alfa class drug whether approved drug or investigational drug\proposed biosimilar.
  9. Intake of an investigational drug in another study within 3 months or 5 half-lives, whichever is longer, before the intake of the IMP in this study or planned intake of an investigational drug during the course of this study.
  10. Use of depot injectable solutions (except for depot contraception drugs) within 6 months before randomization.
  11. Smoking more than equivalent of (as determined by investigator) 10 cigarettes per day and/or inability to refrain from smoking or consuming nicotine containing products during the residential stay at the trial site.
  12. History of alcohol abuse within one year from screening and/or inability to refrain from intake of alcoholic beverages from 48 hours prior to Day -1 until Day 14 postdose or a positive screen for alcohol on admission to the clinical site prior to study drug administration.
  13. Positive screen for drugs of abuse at screening or at admission to the clinical site prior to study drug administration.
  14. Donated more than 450 mL of blood within 60 days or 450 mL of blood products (eg, plasma, platelets) within 2 weeks prior to admission to the clinical site or intend to donate during the study.
  15. Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), dietary supplements or herbal medication during the 2 weeks prior to study drug administration or longer if the medication has a long half-life. For female subjects, oral contraceptives and hormone replacement therapy are allowed.
  16. History of cancer including lymphoma, leukemia, and skin cancer.
  17. Impaired liver function as determined at screening or admission to the clinic by one of the following:

    • Serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >1.5 times the upper limit of normal (ULN) at screening or admission to the clinic.
    • A positive hepatitis C virus (HCV) antibody test or hepatitis B surface antigen (HBsAg) test and/or core antibody test for immunoglobulin G (IgG) and/or immunoglobulin M (IgM) at screening.
  18. History of or current signs or symptoms of demyelinating disease including optic neuritis and/or multiple sclerosis.
  19. History of immunodeficiency (including a positive test for human immunodeficiency virus [HIV] 1 or 2 antibodies) or other clinically significant immunological disorders, or autoimmune disorders, (eg, rheumatoid arthritis, lupus erythematosus, scleroderma).
  20. History of and/or current gastrointestinal, renal, cardiovascular, hematological (including pancytopenia, aplastic anemia or blood dyscrasia), metabolic (including known diabetes mellitus), central nervous system or pulmonary disease considered as significant by the Investigator.
  21. Received a live vaccine within 12 weeks prior to screening visit or plan for any such vaccination during the study or within 4 months after study drug administration.
  22. Any abnormal skin conditions or potentially obscuring tattoos, pigmentation, or lesions in the areas intended for s.c. injection, that in opinion of Investigator do not allow assessment of local tolerability.
  23. Legal incapacity or limited legal capacity.
  24. Significant concurrent disease or a known medical condition which would make the participant unfit to participate in the study as per Investigator assessment.

Sites / Locations

  • PRA Health Sciences (PRA) - Early Development Services (EDS)
  • PRA-EDS

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

40 mg MSB11022 via Auto-injector

40 mg MSB11022 via Pre-filled Syringe

Arm Description

Participants will receive a single dose of 40 mg/0.8 mL of MSB11022 via an auto-injector on Day 1.

Participants will receive a single dose of 40 mg/0.8 mL of MSB11022 via a pre-filled syringe on Day 1.

Outcomes

Primary Outcome Measures

Area Under the Concentration-time Curve from Time Zero to Infinity (AUC0-inf) for MSB11022
Maximum Observed Plasma Concentration (Cmax) for MSB11022
Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) for MSB11022

Secondary Outcome Measures

Time to Reach the Maximum Plasma Concentration (Tmax) for MSB11022
Terminal Rate Constant (λz) for MSB11022
Terminal Half-life (t1/2) for MSB11022
Apparent Total Clearance (CL/F) for MSB11022
Number of Participants with at Least One Treatment-Emergent Adverse Event (TEAE)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment AE. A TEAE is an AE that occurs only once treatment has started.
Number of Participants with at Least One Serious Adverse Event (SAE)
An SAE is defined as an AE occurring during any study phase that fulfills one or more of the following criteria: Results in death. Requires hospitalization (in-patient treatment) or prolongation of existing hospitalization. Is life-threatening. Results in persistent or significant disability or incapacity. Is a congenital anomaly or birth defect. Is otherwise considered to be medically important.
Number of Participants with at Least One Adverse Event of Special Interest (AESI)
An AESI is defined as a hypersensitivity reaction of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or above.
Number of Participants with an Injection Site Reaction (ISR)
Local tolerability will be assessed be evaluating the site of administration. The investigator or designee will check for the presence of injection site reactions, including, erythema, rash, tenderness, swelling, itching, bruising, or other abnormalities.
Number of Participants who Experience a Clinically Significant Change in Vital Sign Results
Vital sign measurements will include Systolic and diastolic blood pressure, pulse, body temperature and respiratory rate.
Number of Participants who Experience a Clinically Significant Change in Clinical Laboratory Results
Parameters will include clinical chemistry, coagulation, hematology, urinalysis and serology.
Number of Participants who Experience a Clinically Significant Change in Electrocardiogram (ECG) Results
A standard 12-lead ECG will be used.

Full Information

First Posted
July 11, 2019
Last Updated
March 23, 2020
Sponsor
Fresenius Kabi SwissBioSim GmbH
Collaborators
PRA Health Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT04018599
Brief Title
Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
Official Title
A Phase I, Randomized, Open-label, Parallel-group Study to Determine the Pharmacokinetics, Safety, and Tolerability of MSB11022 (Proposed Adalimumab Biosimilar) Following a Single Subcutaneous Injection by an Auto-injector or by a Pre-filled Syringe in Healthy Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
July 15, 2019 (Actual)
Primary Completion Date
March 17, 2020 (Actual)
Study Completion Date
March 17, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fresenius Kabi SwissBioSim GmbH
Collaborators
PRA Health Sciences

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective of this study is to demonstrate equivalence of the pharmacokinetic (PK) profile of MSB11022 administered by either an auto-injector (AI) or a pre-filled syringe (PFS) as single subcutaneous (s.c.) injection of 40 mg.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Keywords
Biosimilar, Adalimumab, MSB11022

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
216 (Actual)

8. Arms, Groups, and Interventions

Arm Title
40 mg MSB11022 via Auto-injector
Arm Type
Experimental
Arm Description
Participants will receive a single dose of 40 mg/0.8 mL of MSB11022 via an auto-injector on Day 1.
Arm Title
40 mg MSB11022 via Pre-filled Syringe
Arm Type
Experimental
Arm Description
Participants will receive a single dose of 40 mg/0.8 mL of MSB11022 via a pre-filled syringe on Day 1.
Intervention Type
Drug
Intervention Name(s)
40 mg MSB11022
Intervention Description
Single dose, as a solution, administered subcutaneously, using an auto-injector.
Intervention Type
Drug
Intervention Name(s)
40 mg MSB11022
Intervention Description
Single dose, as a solution, administered subcutaneously, using a pre-filled syringe.
Primary Outcome Measure Information:
Title
Area Under the Concentration-time Curve from Time Zero to Infinity (AUC0-inf) for MSB11022
Time Frame
Pre-dose (-1 hour), 4, 8, 12, 24, 48, 72, 96, 120,144,168, 192, 240, 336, 504, 672, 840,1008, 1344 and 1680 hours post-dose
Title
Maximum Observed Plasma Concentration (Cmax) for MSB11022
Time Frame
Pre-dose (-1 hour), 4, 8, 12, 24, 48, 72, 96, 120,144,168, 192, 240, 336, 504, 672, 840,1008, 1344 and 1680 hours post-dose
Title
Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) for MSB11022
Time Frame
Pre-dose (-1 hour), 4, 8, 12, 24, 48, 72, 96, 120,144,168, 192, 240, 336, 504, 672, 840,1008, 1344 and 1680 hours post-dose
Secondary Outcome Measure Information:
Title
Time to Reach the Maximum Plasma Concentration (Tmax) for MSB11022
Time Frame
Pre-dose (-1 hour), 4, 8, 12, 24, 48, 72, 96, 120,144,168, 192, 240, 336, 504, 672, 840,1008, 1344 and 1680 hours post-dose
Title
Terminal Rate Constant (λz) for MSB11022
Time Frame
Pre-dose (-1 hour), 4, 8, 12, 24, 48, 72, 96, 120,144,168, 192, 240, 336, 504, 672, 840,1008, 1344 and 1680 hours post-dose
Title
Terminal Half-life (t1/2) for MSB11022
Time Frame
Pre-dose (-1 hour), 4, 8, 12, 24, 48, 72, 96, 120,144,168, 192, 240, 336, 504, 672, 840,1008, 1344 and 1680 hours post-dose
Title
Apparent Total Clearance (CL/F) for MSB11022
Time Frame
Pre-dose (-1 hour), 4, 8, 12, 24, 48, 72, 96, 120,144,168, 192, 240, 336, 504, 672, 840,1008, 1344 and 1680 hours post-dose
Title
Number of Participants with at Least One Treatment-Emergent Adverse Event (TEAE)
Description
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment AE. A TEAE is an AE that occurs only once treatment has started.
Time Frame
Day 1 (post-dose) to Day 71
Title
Number of Participants with at Least One Serious Adverse Event (SAE)
Description
An SAE is defined as an AE occurring during any study phase that fulfills one or more of the following criteria: Results in death. Requires hospitalization (in-patient treatment) or prolongation of existing hospitalization. Is life-threatening. Results in persistent or significant disability or incapacity. Is a congenital anomaly or birth defect. Is otherwise considered to be medically important.
Time Frame
Screening (up to 28 days prior to study admission) to Day 71
Title
Number of Participants with at Least One Adverse Event of Special Interest (AESI)
Description
An AESI is defined as a hypersensitivity reaction of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or above.
Time Frame
Screening (up to 28 days prior to study admission) to Day 71
Title
Number of Participants with an Injection Site Reaction (ISR)
Description
Local tolerability will be assessed be evaluating the site of administration. The investigator or designee will check for the presence of injection site reactions, including, erythema, rash, tenderness, swelling, itching, bruising, or other abnormalities.
Time Frame
Day 1 (post-dose) to Day 71
Title
Number of Participants who Experience a Clinically Significant Change in Vital Sign Results
Description
Vital sign measurements will include Systolic and diastolic blood pressure, pulse, body temperature and respiratory rate.
Time Frame
Screening (up to 28 days prior to study admission) to Day 71
Title
Number of Participants who Experience a Clinically Significant Change in Clinical Laboratory Results
Description
Parameters will include clinical chemistry, coagulation, hematology, urinalysis and serology.
Time Frame
Screening (up to 28 days prior to study admission) to Day 71
Title
Number of Participants who Experience a Clinically Significant Change in Electrocardiogram (ECG) Results
Description
A standard 12-lead ECG will be used.
Time Frame
Screening (up to 28 days prior to study admission) to Day 71

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Willing and able to sign the informed consent form (ICF). Healthy male subjects and female subjects of non-childbearing and childbearing potential. Aged 18 to 55 years, inclusive, at screening. Have all screening results (vital signs, physical examination, clinical laboratory tests, 12-lead ECG) within the normal range or outside the normal range but assessed as not clinically significant by the Investigator. Body weight between 50.0 and 100.0 kg, inclusive, and a body mass index between 18.5 and 30.0 kg/m2, inclusive. Male subjects must be either surgically sterile or willing to use contraceptive methods until 5 months after the dose of investigational medicinal product (IMP). Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and before randomization. WOCBP must agree to use highly effective methods of contraception to prevent pregnancy for at least 4 weeks before randomization until 5 months after the dose of IMP. For all postmenopausal female subjects, serum follicle-stimulating hormone (FSH) is tested at screening to identify their postmenopausal status. Willing and able to comply with scheduled visits, treatment plan, laboratory tests and all other study procedures. Exclusion Criteria: Female subjects must not be pregnant or lactating at screening through at least 5 months after the last treatment with IMP. A history and/or current presence of clinically significant atopic allergy (eg, asthma including childhood asthma), hypersensitivity or allergic reactions (either spontaneous or following drug administration), including known or suspected clinically relevant drug hypersensitivity to any components of the study drug formulations, comparable drugs, or to latex. Mild hay fever is allowed if outside of acute exacerbation requiring treatment. Assessment of clinical significance of reported atopic or allergic condition in medical history of participant is at Investigator decision. Have either active or latent tuberculosis (TB) as indicated by a positive QuantiFERON®-TB Gold test or have a history of TB. Subjects who have an indeterminate QuantiFERON-TB Gold test result may be re-tested once during screening. If the re-test result is negative, the subject is eligible to participate in the study. If the re-test result is indeterminate again or positive, the subject is NOT eligible to participate in the study. Lifetime history of invasive systemic fungal infections (eg, histoplasmosis) or other opportunistic infections, including recurrent or chronic local fungal infections. Have had a serious infection (associated with hospitalization and/or which required intravenous anti-infectives or intravenous antibiotics) within 6 months prior to study drug administration and/or a significant infection (excluding resolved infections like a mild common cold) within 2 weeks prior to the screening or during the screening period unless the infection has resolved completely within 2 weeks before admission. Have had herpes zoster within the last year, or more than 2 herpes zoster infections in their lifetime prior to randomization. History or presence (at time of screening or randomization) of frequent (ie, requiring treatment more than 3 times a year), chronic or recurrent infections. Have previously been exposed to adalimumab or approved or proposed adalimumab biosimilar drugs if known. Have been exposed to any anti-tumor necrosis factor alfa class drug whether approved drug or investigational drug\proposed biosimilar. Intake of an investigational drug in another study within 3 months or 5 half-lives, whichever is longer, before the intake of the IMP in this study or planned intake of an investigational drug during the course of this study. Use of depot injectable solutions (except for depot contraception drugs) within 6 months before randomization. Smoking more than equivalent of (as determined by investigator) 10 cigarettes per day and/or inability to refrain from smoking or consuming nicotine containing products during the residential stay at the trial site. History of alcohol abuse within one year from screening and/or inability to refrain from intake of alcoholic beverages from 48 hours prior to Day -1 until Day 14 postdose or a positive screen for alcohol on admission to the clinical site prior to study drug administration. Positive screen for drugs of abuse at screening or at admission to the clinical site prior to study drug administration. Donated more than 450 mL of blood within 60 days or 450 mL of blood products (eg, plasma, platelets) within 2 weeks prior to admission to the clinical site or intend to donate during the study. Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), dietary supplements or herbal medication during the 2 weeks prior to study drug administration or longer if the medication has a long half-life. For female subjects, oral contraceptives and hormone replacement therapy are allowed. History of cancer including lymphoma, leukemia, and skin cancer. Impaired liver function as determined at screening or admission to the clinic by one of the following: Serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >1.5 times the upper limit of normal (ULN) at screening or admission to the clinic. A positive hepatitis C virus (HCV) antibody test or hepatitis B surface antigen (HBsAg) test and/or core antibody test for immunoglobulin G (IgG) and/or immunoglobulin M (IgM) at screening. History of or current signs or symptoms of demyelinating disease including optic neuritis and/or multiple sclerosis. History of immunodeficiency (including a positive test for human immunodeficiency virus [HIV] 1 or 2 antibodies) or other clinically significant immunological disorders, or autoimmune disorders, (eg, rheumatoid arthritis, lupus erythematosus, scleroderma). History of and/or current gastrointestinal, renal, cardiovascular, hematological (including pancytopenia, aplastic anemia or blood dyscrasia), metabolic (including known diabetes mellitus), central nervous system or pulmonary disease considered as significant by the Investigator. Received a live vaccine within 12 weeks prior to screening visit or plan for any such vaccination during the study or within 4 months after study drug administration. Any abnormal skin conditions or potentially obscuring tattoos, pigmentation, or lesions in the areas intended for s.c. injection, that in opinion of Investigator do not allow assessment of local tolerability. Legal incapacity or limited legal capacity. Significant concurrent disease or a known medical condition which would make the participant unfit to participate in the study as per Investigator assessment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Radmila Kanceva, MD, PhD
Organizational Affiliation
Fresenius Kabi SwissBioSim GmbH
Official's Role
Study Director
Facility Information:
Facility Name
PRA Health Sciences (PRA) - Early Development Services (EDS)
City
Lenexa
State/Province
Kansas
ZIP/Postal Code
66219
Country
United States
Facility Name
PRA-EDS
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84124
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
35262901
Citation
Sabet A, Dickerson DS, Kunina EE, Buccarello AL, Monnet J. A Randomised Controlled Trial Comparing the Pharmacokinetics and Tolerability of the Proposed Adalimumab Biosimilar MSB11022 Delivered via Autoinjector and Pre-filled Syringe in Healthy Subjects. Rheumatol Ther. 2022 Apr;9(2):693-704. doi: 10.1007/s40744-022-00432-1. Epub 2022 Mar 9.
Results Reference
derived

Learn more about this trial

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

We'll reach out to this number within 24 hrs